Seaport Therapeutics Inc., a clinical-stage biotechnology company focused on antidepressants and anxiety drugs, raised nearly $255 million in an upsized US initial public offering that priced at the top of its marketed range.
Antidepressant Maker Seaport Raises $255 Million in Upsized IPO
Seaport Therapeutics Inc., a clinical-stage biotechnology company focused on antidepressants and anxiety drugs, raised nearly $255 million in an upsized US initial public offering that priced at the top of its marketed range.
This article was originally published by
Bloomberg Markets
and is republished here under license.
Leave a Reply